c‐MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival

@article{Lee2018cMETOI,
  title={c‐MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival},
  author={Su Jin Lee and Jeeyun Lee and Se Hoon Park and Joon-Oh Park and Ho Yeong Lim and Won Ki Kang and Young Suk Park and Seung Tae Kim},
  journal={Clinical Colorectal Cancer},
  year={2018},
  volume={17},
  pages={165–169}
}
Micro‐Abstract: Mesenchymal‐epithelial transition factor gene (c‐MET) overexpression might be an important biomarker in colorectal cancer (CRC). We evaluated the incidence of c‐MET overexpression and its prognostic significance in 255 patients with metastatic CRC. We found that 15.3% had c‐MET overexpression and c‐MET overexpression was associated with shorter survival. Introduction: Increased mesenchymal‐epithelial transition factor gene (c‐MET) expression in several human malignancies is… Expand
The potential therapeutic and prognostic impacts of the c‐MET/HGF signaling pathway in colorectal cancer
TLDR
The main findings of recent studies investigating the role of c‐MET/HGF signaling pathway in CRC are summarized and the potential of the c‐ MET/H GF signaling pathways in the diagnosis and treatment of CRC is summarized. Expand
SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET
TLDR
SoX13 is a promising prognostic biomarker in patients with CRC, and blocking the HGF/STAT3/SOX13/c-MET axis with crizotinib could be a new therapeutic strategy to prevent SOX13-mediated CRC metastasis. Expand
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
TLDR
It is found that although HGF/c-MET-targeted therapy has led to breakthroughs in certain cancers, monotherapy of targeting HGF / c-MET has failed to demonstrate significant clinical efficacy in most cancers. Expand
Significant function and research progress of biomarkers in gastric cancer
TLDR
This review focuses closely on the important functions of biomarkers in the timely diagnosis and treatment of Gastric cancer, in addition to the advances in the study of certain novel markers in gastric cancer. Expand
A Six-LncRNA Expression Signature Associated with Prognosis of Colorectal Cancer Patients
TLDR
The results revealed the promise of lncRNAs as prognostic biomarkers and functional enrichment analysis of lNCRNAs suggested significant enrichment of cancer related pathways. Expand
The prognostic importance of VEGF-A, PDGF-BB and c-MET in patients with metastatic colorectal cancer
TLDR
A high c-Met expression relationship with worse PFS and low VEGF-A expression associated with poor metastatic overall survival in patients with metastatic colorectal cancer receiving bevacizumab therapies is revealed. Expand
A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
TLDR
Targeting c-MET through SHR-A1403 showed strong preclinical anti-tumour efficacy in pancreatic cancer, suggesting the potential application of c- MET-targeted antibody-drug conjugate treatment for PDAC in clinical practise. Expand
Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer.
TLDR
The importance of MET in epithelial tumorigenesis and the development of antibody-based biotherapeutics, including bispecific antibodies and antibody-drug conjugates, for clinical application are discussed. Expand
HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
Numerous studies have indicated that abnormal activation of the HGF/c-Met signaling pathway can lead to cell proliferation, invasiveness, and metastasis of cancers of the digestive system. Moreover,Expand
MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
TLDR
The importance of MET and/or RON in CRAC tumorigenesis and development of anti-MET, anti-RON, and MET and RON-dual targeting antibody-drug conjugates for clinical application are discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis
TLDR
A meta-analysis of the HR and the 95 % confidence interval indicated a significantly poor overall survival and disease-free survival in patients with high expression levels of c-Met and a subgroup analysis showed that the prognostic effect of the c- met level was similar in different methods and was not associated with disease stages. Expand
c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence
TLDR
c-MET is a new promising target that may help in understanding the pathogenesis of CRC, and to be used as independent prognostic biomarker to predict local disease recurrence in CRC. Expand
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.
TLDR
Slight increases in c-Met copy number can be detected in localized CRCs, but gene amplification is largely restricted to Stage IV primary cancers and liver metastases and is a viable target for a significant subset of advanced CRC. Expand
FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk
TLDR
The results suggest that the selected cellular receptors are suitable for use as biomarkers of survival and tumour progression in CRC and provide additional evidence for receptor interaction, properly clarifying their importance, which could potentially lead to more effective anti-CRC regimens. Expand
The c-Met receptor: Implication for targeted therapies in colorectal cancer
TLDR
The mechanisms of aberrant c-Met signaling in colorectal cancer will be described and on additional roles for c- met receptor through crosstalk with other tyrosine kinase receptors and cell surface proteins in colorescent cancer are discussed. Expand
Expression of the Hepatocyte Growth Factor and C-Met in Colon Cancer: Correlation with Clinicopathological Features and Overall Survival
Aim and background. The hepatocyte growth factor (HGF)/c-Met signaling system has been implicated in the development and progression of colon cancer, but the relationship between the expression ofExpand
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
TLDR
KRAS mutation significantly correlates with a worse outcome in patients treated with cetuximab, whereas no definitive inference can be drawn about the role of BRAF mutation and PTEN loss of expression and Interestingly, IGF1R overexpression seems a favorable prognostic factor in mCRC. Expand
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
TLDR
The biology and clinical significance behind MET proto‐oncogene receptor tyrosine kinase (MET) exon 14 alterations andMET amplification in NSCLC are explored, the role of MET amplification in the setting of acquired resistance to EGFR tyrosINE kinase inhibitor therapy in EGFR‐mutant NSCLCs is explored, and the history of MET pathway inhibitor drug development inNSCLC is highlighted. Expand
c‐met tyrosine kinase receptor expression is associated with abnormal β‐catenin expression and favourable prognostic factors in invasive breast carcinoma
TLDR
This study evaluated c‐met expression in 69 invasive breast carcinomas and statistically analysed this expression with known clinicopathological prognostic parameters and patients' survival. Expand
Potent antitumor activity of cabozantinib, a c‐MET and VEGFR2 inhibitor, in a colorectal cancer patient‐derived tumor explant model
TLDR
The efficacy of cabozantinib is determined in a preclinical CRC patient‐derived tumor xenograft model and potent inhibitory effects on tumor growth are demonstrated in 80% of tumors treated. Expand
...
1
2
3
4
...